	US 12,409,165 B2
	Pharmaceutical composition comprising eltrombopag bis(monoethanolamine)
Luis Nogueiras Nieto, Sant Boi de Llobregat (ES); Lisardo Alvarez Fernandez, Sant Boi de Llobregat (ES); and Rohit Kumar, Sant Boi de Llobregat (ES)
Assigned to Synthon B.V., Nijmegen (NL)
Appl. No. 17/782,425
Filed by SYNTHON B.V., Nijmegen (NL)
PCT Filed Dec. 4, 2020, PCT No. PCT/EP2020/084723 § 371(c)(1), (2) Date Jun. 3, 2022, PCT Pub. No. WO2021/110959, PCT Pub. Date Jun. 10, 2021.
Claims priority of application No. 19214295 (EP), filed on Dec. 6, 2019.
Prior Publication US 2023/0022228 A1, Jan. 26, 2023
Int. Cl. A61K 31/4152 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01)

CPC A61K 31/4152 (2013.01) [A61K 9/0053 (2013.01); A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 9/2833 (2013.01)]

17 Claims

1. A film-coated swallowable tablet comprising eltrombopag bis(monoethanolamine) and pharmaceutically acceptable excipients comprising calcium silicate as diluent and isomalt as diluent;

wherein the calcium silicate is present in an amount of 5 to 15% by weight based on the total weight of the tablet, and the isomalt is present in an amount of 25 to 50% by weight based on the total weight of the tablet.